Literature DB >> 32087019

Analytical and Clinical Performance of Amyloid-Beta Peptides Measurements in CSF of ADNIGO/2 Participants by an LC-MS/MS Reference Method.

Magdalena Korecka1, Michal J Figurski1, Susan M Landau2, Magdalena Brylska1, Jacob Alexander1, Kaj Blennow3,4, Henrik Zetterberg3,4,5,6, William J Jagust2, John Q Trojanowski1,7, Leslie M Shaw1.   

Abstract

BACKGROUND: Cerebrospinal fluid (CSF) amyloid-β1-42 (Aβ42) reliably detects brain amyloidosis based on its high concordance with plaque burden at autopsy and with amyloid positron emission tomography (PET) ligand retention observed in several studies. Low CSF Aβ42 concentrations in normal aging and dementia are associated with the presence of fibrillary Aβ across brain regions detected by amyloid PET imaging.
METHODS: An LC-MS/MS reference method for Aβ42, modified by adding Aβ40 and Aβ38 peptides to calibrators, was used to analyze 1445 CSF samples from ADNIGO/2 participants. Seventy runs were completed using 2 different lots of calibrators. For preparation of Aβ42 calibrators and controls spiking solution, reference Aβ42 standard with certified concentration was obtained from EC-JRC-IRMM (Belgium). Aβ40 and Aβ38 standards were purchased from rPeptide. Aβ42 calibrators' accuracy was established using CSF-based Aβ42 Certified Reference Materials (CRM).
RESULTS: CRM-adjusted Aβ42 calibrator concentrations were calculated using the regression equation Y (CRM-adjusted) = 0.89X (calibrators) + 32.6. Control samples and CSF pools yielded imprecision ranging from 6.5 to 10.2% (Aβ42) and 2.2 to 7.0% (Aβ40). None of the CSF pools showed statistically significant differences in Aβ42 concentrations across 2 different calibrator lots. Comparison of Aβ42 with Aβ42/Aβ40 showed that the ratio improved concordance with concurrent [18F]-florbetapir PET as a measure of fibrillar Aβ (n = 766) from 81 to 88%.
CONCLUSIONS: Long-term performance assessment substantiates our modified LC-MS/MS reference method for 3 Aβ peptides. The improved diagnostic performance of the CSF ratio Aβ42/Aβ40 suggests that Aβ42 and Aβ40 should be measured together and supports the need for an Aβ40 CRM. © American Association for Clinical Chemistry 2020. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Alzheimer’s disease; abeta42/abeta40 ratio; amyloid beta; certified reference material; mass spectrometry

Mesh:

Substances:

Year:  2020        PMID: 32087019      PMCID: PMC7108496          DOI: 10.1093/clinchem/hvaa012

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  36 in total

1.  A novel pathway for amyloid precursor protein processing.

Authors:  Erik Portelius; Eric Price; Gunnar Brinkmalm; Mark Stiteler; Maria Olsson; Rita Persson; Ann Westman-Brinkmalm; Henrik Zetterberg; Adam J Simon; Kaj Blennow
Journal:  Neurobiol Aging       Date:  2009-07-14       Impact factor: 4.673

2.  Amyloid-β imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods.

Authors:  Susan M Landau; Christopher Breault; Abhinay D Joshi; Michael Pontecorvo; Chester A Mathis; William J Jagust; Mark A Mintun
Journal:  J Nucl Med       Date:  2012-11-19       Impact factor: 10.057

3.  To harmonize and standardize: making measurement results comparable.

Authors:  Ingrid Zegers; Heinz Schimmel
Journal:  Clin Chem       Date:  2014-05-05       Impact factor: 8.327

4.  Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment.

Authors:  Shorena Janelidze; Josef Pannee; Alvydas Mikulskis; Ping Chiao; Henrik Zetterberg; Kaj Blennow; Oskar Hansson
Journal:  JAMA Neurol       Date:  2017-12-01       Impact factor: 18.302

Review 5.  Brain-specific proteins in cerebrospinal fluid for the diagnosis of neurodegenerative diseases.

Authors:  M M Verbeek; D De Jong; H P H Kremer
Journal:  Ann Clin Biochem       Date:  2003-01       Impact factor: 2.057

6.  Relationships between biomarkers in aging and dementia.

Authors:  W J Jagust; S M Landau; L M Shaw; J Q Trojanowski; R A Koeppe; E M Reiman; N L Foster; R C Petersen; M W Weiner; J C Price; C A Mathis
Journal:  Neurology       Date:  2009-10-13       Impact factor: 9.910

7.  Qualification of a surrogate matrix-based absolute quantification method for amyloid-β₄₂ in human cerebrospinal fluid using 2D UPLC-tandem mass spectrometry.

Authors:  Magdalena Korecka; Teresa Waligorska; Michal Figurski; Jon B Toledo; Steven E Arnold; Murray Grossman; John Q Trojanowski; Leslie M Shaw
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

8.  Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer's Disease.

Authors:  Piotr Lewczuk; Anja Matzen; Kaj Blennow; Lucilla Parnetti; Jose Luis Molinuevo; Paolo Eusebi; Johannes Kornhuber; John C Morris; Anne M Fagan
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

Review 9.  NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.

Authors:  Clifford R Jack; David A Bennett; Kaj Blennow; Maria C Carrillo; Billy Dunn; Samantha Budd Haeberlein; David M Holtzman; William Jagust; Frank Jessen; Jason Karlawish; Enchi Liu; Jose Luis Molinuevo; Thomas Montine; Creighton Phelps; Katherine P Rankin; Christopher C Rowe; Philip Scheltens; Eric Siemers; Heather M Snyder; Reisa Sperling
Journal:  Alzheimers Dement       Date:  2018-04       Impact factor: 21.566

10.  CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease.

Authors:  Shorena Janelidze; Henrik Zetterberg; Niklas Mattsson; Sebastian Palmqvist; Hugo Vanderstichele; Olof Lindberg; Danielle van Westen; Erik Stomrud; Lennart Minthon; Kaj Blennow; Oskar Hansson
Journal:  Ann Clin Transl Neurol       Date:  2016-01-01       Impact factor: 4.511

View more
  7 in total

Review 1.  Detection of Alzheimer Disease Pathology in Patients Using Biochemical Biomarkers: Prospects and Challenges for Use in Clinical Practice.

Authors:  Leslie M Shaw; Magdalena Korecka; Michal Figurski; Jon Toledo; David Irwin; Ju Hee Kang; John Q Trojanowski
Journal:  J Appl Lab Med       Date:  2020-01-01

2.  Microglial Activation, Tau Pathology, and Neurodegeneration Biomarkers Predict Longitudinal Cognitive Decline in Alzheimer's Disease Continuum.

Authors:  Yi-He Chen; Rong-Rong Lin; Hui-Feng Huang; Yan-Yan Xue; Qing-Qing Tao
Journal:  Front Aging Neurosci       Date:  2022-06-30       Impact factor: 5.702

3.  Association of CSF Aβ, amyloid PET, and cognition in cognitively unimpaired elderly adults.

Authors:  Tengfei Guo; Leslie M Shaw; John Q Trojanowski; William J Jagust; Susan M Landau
Journal:  Neurology       Date:  2020-08-05       Impact factor: 9.910

4.  An automated clinical mass spectrometric method for identification and quantification of variant and wild-type amyloid-β 1-40 and 1-42 peptides in CSF.

Authors:  Mari L DeMarco; Quyen Nguyen; Alice Fok; Ging-Yuek Robin Hsiung; J Grace van der Gugten
Journal:  Alzheimers Dement (Amst)       Date:  2020-06-30

5.  The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNI-3 updates and global perspectives.

Authors:  Christopher J Weber; Maria C Carrillo; William Jagust; Clifford R Jack; Leslie M Shaw; John Q Trojanowski; Andrew J Saykin; Laurel A Beckett; Cyrille Sur; Naren P Rao; Patricio Chrem Mendez; Sandra E Black; Kuncheng Li; Takeshi Iwatsubo; Chiung-Chih Chang; Ana Luisa Sosa; Christopher C Rowe; Richard J Perrin; John C Morris; Amanda M B Healan; Stephen E Hall; Michael W Weiner
Journal:  Alzheimers Dement (N Y)       Date:  2021-12-31

Review 6.  Mass spectrometry-based methods for robust measurement of Alzheimer's disease biomarkers in biological fluids.

Authors:  Magdalena Korecka; Leslie M Shaw
Journal:  J Neurochem       Date:  2021-08-25       Impact factor: 5.546

7.  Normalization of CSF pTau measurement by Aβ40 improves its performance as a biomarker of Alzheimer's disease.

Authors:  Tengfei Guo; Deniz Korman; Renaud La Joie; Leslie M Shaw; John Q Trojanowski; William J Jagust; Susan M Landau
Journal:  Alzheimers Res Ther       Date:  2020-08-15       Impact factor: 6.982

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.